TMEM52B and ovarian cancer: Interestingly, SNHG25, known for promoting ovarian cancer progression [38], and TMEM52B, associated with EGFR and E-cadherin modulation and tumor/metastasis suppression [39], significantly decreased with KPT-9274 treatment (Fig. 5B, C).